IBSA
4.8.2022 13:02:07 CEST | Business Wire | Press release
Latest-generation Class40, “scow” bow, five months of production: the IBSA craft with which Alberto Bona will participate in the Route du Rhum in November was launched yesterday in La Trinité-Sur-Mer (Brittany, France). It’s the first project of the three-year program Sailing into the Future. Together that the ocean sailor started in early 2022, together with the Swiss pharmaceutical company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802005581/en/
Designed by Sam Manuard , one of the great French naval architects when it comes to ocean classes, the IBSA Class40 was built by the JPS Production shipyard. It’s a Mach 5 model, the latest evolution of Manuard’s Class40, and will be present at the start of the Route du Rhum as one of the most innovative and modern boats. Much attention will surely be drawn to the rounded bow, created with the aim of increasing performance when sailing downwind, but also the hull promises high performance, thanks to the shape of the water lines and appendages, designed to make it a fast all-rounder when reaching too. Distinctive is also the design of the cockpit, large and well protected: a choice that will allow the sailor to face navigation in the most comfortable and safe positions possible. “This boat perfectly reflects our approach to the program ”, summarised Alberto Bona . “It’s the result of the search for detail, of the improvement in every single aspect: we were looking for a fast hull, clearly at the limits of the box rule, reliable in all weather conditions and sufficiently innovative to make a difference ”.
The project Sailing into the Future. Together started from scratch last January with a partnership – that between IBSA and Alberto Bona – born on common grounds and values, with the aim of using sailing as a corporate communication vehicle towards the market and the nautical world. “Ingenuity, courage, innovation, responsibility are elements which unite us - explained Bona - for this reason we are facing together this challenge, which is clearly sporting but which also metaphorically represents the Company's history, philosophy and vision always turned towards the future, and is part of a path bringing IBSA ever closer to environmental and social sustainability, inclusion and integration. In this type of challenge, the solitary navigator stands out but, as in the industry, the commander exists as a function of his team. With IBSA, we first of all built a team ”.
As for the team , we start with Sidney Gavignet as a coach: the very experienced French navigator laid the foundations and objectives, with a strict rule: always be prepared, to foresee all aspects of the challenge, on land and at sea. “Sidney put us in a position to divide this great challenge into many small steps. A long roadmap of stages to be reached, training and testing in preparation for the start, since building a challenge like the Route du Rhum from scratch in seven months is extremely demanding ”. For the physical preparation part, Bona relied on Andrea Madaffari : he has been working with him for months on endurance and strength, as well as on the management of the energy peaks necessary during a regatta. “When sailing, one needs stamina and does a lot of pulling and hauling: you pull sheets and halyards, you need endurance and peak strength ”, explained Bona . “We are working on this, as well as on the aerobic part ”.
“The choice of Sam Manuard as a designer was virtually natural ,” recalled Bona , and is based on a solid relationship dating back to the time of the Mini class, on the sharing of a design vision and on the innovations that Bona was looking for his IBSA Class40. On the sails front, Bona chose Remi Aubrum , whom he entrusted with the choice of innovative materials, compatible with the rigorous box rule of the Class40. The last operational entry is that of the Boat Captain, the Breton expert Pierre-Edouard Regaud .
“In recent months we have all been working with the same philosophy, that of the goals to be achieved day by day. We are working on fatigue management, on finding the best solutions in all aspects of the project. It was a huge team effort, between us and IBSA , that led us to yesterday’s technical launch ”, said Bona .
In the afternoon, at 5 pm, the IBSA Class40 made on board a truck the short journey between the shipyard and the marina that will host it, which is located in front of “Casa IBSA”, the operational headquarters . Alberto Bona now has one month to set up the boat and to qualify, by sailing a thousand miles by the end of August. On September 9, the actual launch – the ceremony that will officially make the Class40 enter the IBSA world – will take place in La Trinité-sur-Mer . In mid-September, Bona will participate in the Malouine Lamotte regatta; then, he will transfer his operational base to Saint-Malo, from where the first regatta of the three-year program will start.
“We will talk to sailing enthusiasts and to the entire IBSA world, ” explained Bona , who also underlines the existence of a comprehensive sustainability project, in common with IBSA : “Navigators are experts in circular economy; they live for long periods on the ocean, they replace fossil fuels with solar and wind energy, they recycle everything they can, they live in true harmony with the sea, that they help protect: this is a very important message that, together with IBSA, we wish to promote and share, using the solo oceanic challenge as a great metaphor of what can and must be done for the environment ”.
In its program associated with sailing, IBSA is also committed to inclusiveness: in fact, the inclusive sailing project involving the Associazione Velabili based at the Circolo Velico Lago di Lugano (Switzerland), the Société des Régates d’Antibes (France) and the Yacht Club Punta Ala (Italy) has also been activated. The project aims to support inclusive sailing by promoting initiatives involving people with disabilities in experiences in contact with the sea and the sailing world, and consists in supporting a team of disabled sailors in participating in the Special Olympics World Games of 2023 and in the purchase of Hansa 303 boats for the Clubs of Punta Ala and Antibes.
IBSA
IBSA (Institut Biochimique SA ) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005581/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
